Mouse models play a critical role in linking together cancer biology, drug discovery and developmental therapeutics, and are a necessary step to test the clinical relevance of basic observation to human cancer (translational research). Over the last several years, imaging modalities have revolutionized the use of murine models as preclinical models by providing new tools to longitudinally and quantitatively monitor cancer progression and response to therapy in these models. The overall goal of the Small Animal Model and in vivo Imaging Core (Core D) is therefore to provide well established and standardized preclinical murine models to test biological hypotheses and novel therapeutic modalities as well as standardized and state of the art imaging technologies to more accurately and efficiently monitor tumor progression and therapeutic response.
The specific aims of this core are therefore:
Aim #1 : To be a central resource providing a series of standardized neuroblastoma xenograft models including subcutaneous injection, orthotopic implantation, experimental bone metastasis and bone invasion models, performing daily tumor monitoring, and administering therapeutic agents. The core will also perform euthanasia and provide tissue suitable for analysis to individual investigators or to core B.
Aim #2 : To be a central resource for the performance of in vivo imaging using high resolution X-rays, optical imaging techniques, microMagnetic Resonance Imaging (MRI) and radionuclide based Single Photon Emission Computer Tomography (SPECT), and to provide expertise for acquisition, interpretation and analysis of imaging data. This core will be a critical link between Project 1, 2 and 3 and project 4 by generating preclinical data identifying novel therapeutic modalities to be then tested and validated in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081403-09
Application #
7719723
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
9
Fiscal Year
2008
Total Cost
$66,209
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
052277936
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Villablanca, Judith G; Ji, Lingyun; Shapira-Lewinson, Adi et al. (2018) Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer 65:e26940
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Webb, Matthew W; Sun, Jianping; Sheard, Michael A et al. (2018) Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer 143:1483-1493
Cho, Hwang Eui; Min, H Kang (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117-124
Zheng, Tina; Ménard, Marie; Weiss, William A (2017) Neuroblastoma Metastases: Leveraging the Avian Neural Crest. Cancer Cell 32:395-397
Erdreich-Epstein, Anat; Singh, Alok R; Joshi, Shweta et al. (2017) Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget 8:52193-52210
Marachelian, Araz; Villablanca, Judith G; Liu, Cathy W et al. (2017) Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res 23:5374-5383
Borriello, Lucia; Nakata, Rie; Sheard, Michael A et al. (2017) Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res 77:5142-5157

Showing the most recent 10 out of 150 publications